Dysregulation of the UPS (ubiquitin-proteasome system) has been implicated in a wide range of pathologies including cancer, neurodegeneration and viral infection. Inhibiting the proteasome has been shown to be an effective therapeutic strategy in humans; however, toxicity with this target remains high. E3s (Ub-protein ligases) represent an alternative attractive therapeutic target in the UPS. In this paper, we will discuss current platforms that report on E3 ligase activity and can detect E3 inhibitors, and underline the advantages and disadvantages of each approach.
Introduction
The conjugation of Ub (ubiquitin) is an important regulatory mechanism that is widespread in many biological processes. Many diseases have been linked to this pathway, making the associated enzymes particularly interesting for therapeutic targets. The UPS (Ub-proteasome system) has been validated with the approval of the proteasome inhibitor bortezomib for the treatment of multiple myeloma; however, significant toxicities were seen during clinical trials, suggesting the need for more selective targets that do not affect all substrates targeted for destruction in the cell [1] [2] [3] [4] . Ubiquitylation is temporally and spatially controlled with strict substrate specificity. To target a protein for degradation by the proteasome, a polyubiquitin chain must be covalently attached to the protein at a lysine residue. It is the polyubiquitin chain that is recognized by the proteasome and results in the degradation of the attached protein. Three classes of enzyme, E1 (Ub-activating enzyme), E2 (Ubconjugating enzyme) and E3 (Ub-protein ligase) mediate the reaction. The E1 first activates a free Ub in an ATPdependent manner, forming a high-energy thioester bond between the E1's active-site cysteine residue and the Cterminus of Ub. The activated Ub is then transferred to an E2, forming a similar thioester linkage. On recognizing a specific substrate and recruiting an E2, the E3 ligase mediates the Ub transfer from the E2 to the lysine residue(s) of the substrate. Mono-ubiquitylation, resulting in protein functionalization, is also possible with the corresponding E2 enzyme. Similar mechanisms can also be found in the UBL (Ub-like) protein pathways, e.g. NEDD8 (neural-precursorcell-expressed developmentally down-regulated 8), SUMO Key words: high-throughput screening, homologous with E6-associated protein C-terminus (HECT), RING, ubiquitin-protein ligase (E3). Abbreviations used: APC, allophycocyanin; FRET, fluorescence resonance energy transfer; GST, glutathione transferase; HECT, homologous with E6-associated protein C-terminus; HRP, horseradish peroxidase; HTS, high-throughput screening; Mdm2, murine double minute 2; Skp1, S-phase kinase-associated protein 1; SCF, Skp1/cullin/F-box; TAMRA, 6-carboxytetramethylrhodamine; β-TrCP, β-transducin repeat-containing protein; Ub, ubiquitin; UBD, Ub-binding domain; UBL, Ub-like; UPS, Ub-proteasome system. 1 To whom correspondence should be addressed (email goldenberg@progenra.com).
(small ubiquitin-related modifier) and ISG15 (interferonstimulated gene 15) (reviewed in [5] ).
Ub ligases (E3s) represent an alternative target in the UPS that should yield compounds with toxicity profiles that are superior to that of a proteasome inhibitor [6, 7] . There are two classes of E3: RING E3s, which act as scaffolds to bring the components of the ubiquitylation machinery together in close contact with the substrate, and HECT (homologous with E6-associated protein C-terminus) E3s, which form an intermediate with Ub before transferring it to the substrate. To develop therapeutic agents that target E3s, it is important to have a readily quantifiable assay platform that is suitable for HTS (high-throughput screening). To date, only one inhibitor of E3s has reached clinical trials [8] , demonstrating that current assay technologies need to be improved to find compounds that translate from the in vitro assay to the clinic. Here, we will provide an overview of current E3 HTS approaches and discuss the advantages and disadvantages of each.
Druggability of Ub ligases
The approval of the proteasome inhibitor bortezomib (VELCADE ® ) for the treatment of multiple myeloma validated the targeting of the Ub-proteasome pathway (UPS) for the treatment of cancer. However, extended treatment with bortezomib is associated with toxicity and drug resistance, limiting its efficacy [1] [2] [3] [4] . E3 ligases represent an attractive drug target in the UPS because of their limited number of substrates and selective regulatory pathways. One of the most interesting E3 targets is the SCF [Skp1 (S-phase kinase-associated protein 1)/cullin/F-box] [9] . The cullin and the cullin-like family share a conserved cullin homology domain among the five human cullins (Cul1, Cul2, Cul3, Cul4A/Cul4B and Cul5) and three cullin-like proteins (Apc2, Cul7 and Parc) that have been identified. All of the proteins in the cullin superfamily bind a RING domain protein, ROC1 (RING of cullins 1), and together form the core of a scaffold that creates multi-subunit RING UBL ligases. The [47] , TRIM [48] remainder of the scaffold is made up of adaptor proteins, F-box proteins, which bind a large variety of substrates and allow the regulation of an extensive variety of cellular functions. Two therapeutically relevant F-box proteins that are targeted for drug discovery are Skp2 and β-TrCP (β-transducin repeat-containing protein) because of the key roles they play in cell cycle progression [10, 11] . However, to inhibit these proteins, one must disrupt a protein-protein interaction, typically considered more difficult to target than an enzymatic catalytic site, but not impossible with recent advances in understanding these interactions [12] . It is also important to consider that in a typical ubiquitylation reaction, not only is an E3 and an associated substrate present, but also E1 and E2 enzymes. This makes follow-up assays important for the deconvolution of any lead compounds in an HTS campaign to determine which enzyme is being affected. In contrast with the RING E3s, the HECT E3s have intrinsic catalytic activity characterized by an active cysteine residue that forms a thioester with Ub from an E2. This intermediate allows for the E3 to transfer Ub directly to the substrate. Notably, this transfer requires a conformational change in the HECT domain [13] . Altogether, the HECT E3s are considered to be more amenable to inhibition relative to RING E3s [6] . Both classes of E3 are involved in numerous diseases (Table 1) and HTS campaigns to find inhibitors need to consider the advantages and disadvantages of each approach.
Current assay systems for Ub ligases
Unbound reaction components E3 ligases facilitate the covalent attachment of Ub to a target substrate, which results in an increase in proximity of these two proteins. This action allows for the use of FRET (fluorescence resonance energy transfer), a commonly used technology for HTS. The principle of this assay relies on two individually fluorescently labelled proteins; one of which acts as the fluorescent protein donor, while the other acts as the acceptor. When these proteins are brought into close proximity, energy is transferred between the donor and acceptor, wherein the acceptor emission can be detected following donor excitation. In contrast, when the two proteins are dissociated, only the donor emission is detectable after donor excitation. The ratio between donor and acceptor emissions reports on the relative interaction between two populations of proteins.
Several groups have used FRET technology to screen for inhibitors of E3 auto-ubiquitylation and substrate ubiquitylation. Although different formats have been applied, the basic idea is the same. Ub is labelled with one of the FRET pairs, commonly the FRET donor Eu 3+ . When the substrate or E3, frequently labelled with the FRET acceptor APC (allophycocyanin), is ubiquitylated, the FRET pairs are brought into close proximity and a shift towards APC's λ em (665 nm) is seen. An example of this assay is illustrated in Figure 1(A) [14] . This technique has the advantage that all enzymes are free in solution to interact. This approach was used to detect Mdm2 (murine double minute 2) ubiquitylation of p53 by labelling p53 with Eu 3+ and Ub with Cy5 [15] . A different approach used a mixture of Ub labelled with either fluorescein or TAMRA (6-carboxytetramethylrhodamine); when polyubiquitin chains are formed, the fluorescein-Ub acts as a donor for the TAMRA-Ub in the chain, allowing for the detection of chain assembly [16] .
In addition to the ubiquitylation of p53 discussed above [17] , solution-based FRET assays have been shown to work for auto-ubiquitylation for the E3s Rsc [14] and TRAF6 (tumour-necrosis-factor-receptor-associated factor 6) [18] . However, there are some problems with this approach. First, the distance between the FRET pairs has a significant impact on the signal. The Förster R 0 value (the distance at which there is a 50% energy transfer between the pair) can be limiting as several E3s and substrates can easily span 70-80 Å (1 Å = 0.1 nm) [19] . One must take great care in choosing where the labelling is done and the situation can be further complicated by the fact that the substrate or E3 is not always labelled directly, but is frequently expressed with a fusion tag, which in turn binds an associated matrix that is labelled with APC. This further increases the distance between the FRET donor and acceptor and, consequently, decreases the signal that can be achieved in the assay. In many cases, the components are no longer native during the assay, as they are pre-bound to a matrix in addition to a fusion tag. While these assays do not have wash steps, making the procedure and equipment required more accessible, it does open up the possibility for the compounds in the assay to cause background fluorescence and interference. To resolve this problem, the compounds must be kept at low concentrations, which might not be optimal for primary screening, depending on the composition of the compound library.
An alternative approach has been used to detect inhibitors of a HECT E3, Rsc [14] . First, a GST (glutathione transferase)-Rsc ubiquitylation reaction was conducted using biotin-labelled Ub. After Rsc auto-ubiquitylation, the reaction was transferred to streptavidin-coated plates. After several wash steps, anti-GST Eu 3+ antibody was added and detected after washing. An inhibitor would cause a decrease in the signal emitted by Eu 3+ as less biotin-Ub-Rsc-GST would be bound in the well. Notably, this approach also requires not only multiple wash steps but also a transfer step, and this decreases the throughput and increases the hardware requirements. The tags on the proteins could also cause interference. In a similar format, 125 I-labelled Ub has also been used, in which case quantification was performed by scintillation spectrometry [17] . In these two approaches, the components are free during the reaction and are immobilized only after the reaction has been given time to reach completion.
Immobilization of E3s in HTS
Detecting auto-ubiquitylation of an E3 Ub ligase is an established method for HTS campaigns to find inhibitors, in the hope that inhibition of auto-ubiquitylation would translate to inhibition of substrate ubiquitylation. Typically, an E3 is immobilized to a plate or a bead by non-specific interactions or affinity tags; the E3 can then undergo autoubiquitylation when the E1, E2, Ub and ATP are present. Unbound reaction components are removed by washing steps and a pre-labelled Ub or anti-Ub antibody is used to quantify the amount of polyubiquitylated E3.
This approach is open to many different options for immobilization and detection. One of the best characterized assays of this type was developed by Meso-Scale Discovery [20] and utilizes the ORIGEN-tag-labelled anti-Ub antibody to produce an electrochemiluminescence signal that is read on an ORIGEN M-8 Analyzer ( Figure 1B) . In this case, GSTfused E3 is immobilized on GSH-magnetic beads followed by E3 auto-ubiquitylation. The M8 analyser allows for the separation of bound from unbound Ub samples, significantly reducing background, and the amount of Ub is determined by chemiluminescence after the addition of antibody.
This approach utilizes a GST tag, which could interfere with potential compound binding sites. Also, immobilizing the E3 to a bead prior to the reaction may inhibit the ability of the E3 to function, particularly HECT E3s, which undergo significant conformational changes during the ubiquitylation process [13] . While E3 auto-ubiquitylation could be an indicator of substrate ubiquitylation, it is not guaranteed and one must follow up to confirm that substrate ubiquitylation is indeed inhibited.
Immobilization of E3 substrates in HTS
One way to be sure that a substrate is being ubiquitylated is to immobilize the substrate prior to a reaction and monitor for its ubiquitylation state. One group has carried out this approach in an ELISA-based format using 1536-well plates ( Figure 1C ) [21] . High-binding assay plates were incubated with substrate solution for 3 h at room temperature. After the unbound substrate was removed, the E1 and E2 enzymes were added to the plate with ATP and FLAG-Ub to pre-charge the E2 with Ub and decrease the chance of finding E1 or E2 inhibitors. The compound and E3 ligase were then added and, after the reaction was run for 1 h, the plates were washed to stop the reaction. Anti-FLAG HRP (horseradish peroxidase) was incubated on the plates for 30 min and removed and HRP substrate was then added. A compound that inhibited substrate ubiquitylation would result in a decrease in HRP reaction product.
Monitoring substrate ubiquitylation gives the greatest chance of finding a highly specific inhibitor with the lowest predicted toxicity profile. This is especially true for the SCF family of Ub ligases, which have numerous adaptors and substrates. The major disadvantage of this approach is immobilizing the substrate and not knowing how the substrate is bound to the plate. Native sites for compound interaction could be blocked based on the substrate's orientation after binding to the plate, making it important to determine the exact site on the substrate that is being targeted for ubiquitylation to confirm that it is mimicking a native assay.
Immobilization of UBD (Ub-binding domain)
An alternative approach to all of the techniques described above is to exclusively capture polyubiquitylated proteins from a reaction [22] . This format could be applied to substrate ubiquitylation, E3 auto-ubiquitylation, or potentially even an E3-independent E2 polyubiquitin chain. As shown in Figure 1(D) , all reaction components are free in solution and are only bound once a polyubiquitin chain is formed, which is subsequently recognized by an immobilized UBD. The proteins do not have to have any kind of protein tag or direct labelling, allowing for truly native protein interactions. This permits an exploration of chemical space that is most similar to that encountered in a cell. The first compounds discovered using this approach are in early-stage pre-clinical development.
Future of Ub ligase screening and potential therapies
Several Ub ligases have been deemed to be good therapeutic targets (Table 1 ) and the first small-molecule inhibitors targeting an E3, in this case Mdm2, are now in clinical trials [8] . E3 HTS assays are difficult due to the number of functional proteins and enzymes that are required and frequently require deconvolution to eliminate the E1 and E2 inhibitors. However, the promise of increased specificity and reduced toxicity over proteasome inhibitors and the recent entry of compounds into clinical trials is drawing more attention to these potential therapeutic targets from the pharmaceutical industry. With the recent introduction of the Ub-binding HTS assay that utilizes all native proteins, as opposed to labelled or immobilized targets that have been used previously, we predict that the likelihood of obtaining E3 inhibitors with improved potency and selectivity is increased. 
